Tuesday, 21 Jan 2020

You are here

Mixed Results with Combination Therapy in Gout

Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.

CRYSTAL was a 12 month study of 324 patients with tophaceous gout assessed the efficacy of lesinurad in combination with febuxostat. Patients were required to have an elevated serum urate (sUA) ≥8.0 mg/dl (or ≥6.0 mg/dl on ULT) and a measurable target tophus; and had to be on febuxostat 80mg daily for 3 weeks before randomization to lesinurad (200 or 400mg daily) or placebo.

Primary endpoint was achieving sUA <5.0 mg/dl by month 6 and the secondary end point was complete tophus resolution.

Significantly more patients achieved sUA < 5.0 with lesinurad 400mg (76.1%; P<0.0001) compared to placebo. The lesinurad 200mg dose was not significantly different (56.6%; P=0.13), than placebo and febuxostat (46.8%).

While tophus resolution on lesinurad was numerically (nearly 50% reduction) better than placebo at 12 months, this did not achieve statistical significance.

Safety findings were similar with the exception of higher rates of reversible serum creatinine elevation with lesinurad 400mg.

These data suggest that lesinurad in combination with febuxostat demonstrated superior sUA lowering compared with febuxostat alone, with clinically relevant impact on tophi resolution. 

The limited efficacy of the 200 mg dose and renal risks with the 400 mg dose of lesinurad may limit the use of this agent in many patients with gout.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.